Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: Sorafenib
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Trial Timeline
Jan 28, 2016 → Jul 10, 2019
NCT ID
NCT02624700About Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: Sorafenib
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: Sorafenib is a phase 2 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02624700. Target conditions include Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02624700 | Phase 2 | Terminated |
Competing Products
20 competing products in Breast Cancer